Early Development of Ubiquitous Acanthocytosis and Extravascular Hemolysis in Lung Cancer Patients Receiving Alectinib

SIMPLE SUMMARY: ALK translocation is present in 4–5% of patients with non-small-cell lung cancer. Patients treated with alectinib invariably develop subclinical hemolysis, which is presumably caused by acanthocytic deformation and splenic trapping of blood erythrocytes. Morphologic red blood cell ch...

Descripción completa

Detalles Bibliográficos
Autores principales: Kunz, Julia, Wiedemann, Christiane, Grosch, Heidrun, Kriegsmann, Katharina, Gryzik, Stefanie, Felden, Julia, Hundemer, Michael, Seker-Cin, Huriye, Stenzinger, Miriam, Leo, Albrecht, Stenzinger, Albrecht, Thomas, Michael, Christopoulos, Petros
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9179520/
https://www.ncbi.nlm.nih.gov/pubmed/35681698
http://dx.doi.org/10.3390/cancers14112720

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9179520/
https://www.ncbi.nlm.nih.gov/pubmed/35681698
http://dx.doi.org/10.3390/cancers14112720

Ejemplares similares